Leerink Partnrs Has Negative Outlook of XENE FY2026 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Analysts at Leerink Partnrs reduced their FY2026 EPS estimates for Xenon Pharmaceuticals in a research report issued to clients and investors on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will post earnings of ($3.54) per share for the year, down from their previous forecast of ($3.40). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.05). During the same quarter last year, the business posted ($0.72) EPS.

Several other analysts also recently issued reports on the company. William Blair upgraded Xenon Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 target price on shares of Xenon Pharmaceuticals in a report on Friday, August 9th. HC Wainwright initiated coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, October 1st. They issued a “buy” rating and a $53.00 price target on the stock. Wedbush dropped their price objective on shares of Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Finally, Raymond James reissued an “outperform” rating and issued a $50.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Eleven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $57.45.

Xenon Pharmaceuticals Stock Up 3.6 %

Shares of NASDAQ:XENE opened at $44.86 on Friday. The stock has a market cap of $3.39 billion, a PE ratio of -16.55 and a beta of 1.25. Xenon Pharmaceuticals has a 12-month low of $27.99 and a 12-month high of $50.99. The business has a 50 day moving average of $40.00 and a 200-day moving average of $40.17.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new position in Xenon Pharmaceuticals in the first quarter valued at approximately $17,941,000. Affinity Asset Advisors LLC increased its stake in shares of Xenon Pharmaceuticals by 82.0% in the 1st quarter. Affinity Asset Advisors LLC now owns 837,387 shares of the biopharmaceutical company’s stock valued at $36,050,000 after purchasing an additional 377,387 shares during the last quarter. Logos Global Management LP acquired a new position in shares of Xenon Pharmaceuticals during the 2nd quarter worth $14,621,000. Ikarian Capital LLC lifted its position in shares of Xenon Pharmaceuticals by 169.6% during the 1st quarter. Ikarian Capital LLC now owns 107,187 shares of the biopharmaceutical company’s stock worth $4,614,000 after buying an additional 261,276 shares during the last quarter. Finally, Artal Group S.A. acquired a new stake in Xenon Pharmaceuticals in the first quarter valued at about $10,908,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.